mCRPC 3 FDA批准mCRPC治疗诊断放射性药物的I期试验 2025/06/20 Phase 3 trial launches of ifinatamab deruxtecan vs chemotherapy in mCRPC 2025/06/18 FDA does not approve talazoparib plus enzalutamide for non-HRR gene mutated mCRPC 2025/06/17